期刊文献+

唑来膦酸联合放疗治疗骨转移癌的临床分析 被引量:8

在线阅读 下载PDF
导出
摘要 骨转移是恶性肿瘤最常见的转移部位,骨转移癌的发生率为30%~85%,比原发性骨肿瘤高,其中80%由乳腺癌、前列腺癌和肺癌引起。我科自2009年5月~2011年5月对128例骨转移癌患者采用单独放疗或联合唑来膦酸进行治疗,现将结果报告如下。
机构地区 海口市人民医院
出处 《实用癌症杂志》 2012年第4期415-416,共2页 The Practical Journal of Cancer
  • 相关文献

参考文献10

  • 1谷铣之,殷蔚伯,余子豪,等.肿瘤放射治疗学[M].北京:中国协和医科大学出版社,2008:573.
  • 2Hoakin P, Makin W. Oncology for Palliative Medicine[M].2nd ed. NeW York : Oxford University Press ,2003:271-289.
  • 3Coukell A J, Markham A. Pamidronate : a review of its use in osteolytic bone metastases, tumour-induced hyperealcaemia and Paget, s disease of bone[J]. Drugs&Aging, 1998,12 (2) : 149.
  • 4Green JR, Muller K, Jaegg KA. Preclinical pharmacology of CGP 42446 : a new, potent, heterocyclic bisphosphonate compound [J]. J Bone Miner Res, 1994,9 ( 5 ) :745.
  • 5Rogers MJ,Gordon S,Frith JC,et al. New insights into the molecular mechanisms of action of bisphosphonates[J]. Curr Pharm Des,2003, 9(32) :2643.
  • 6Senaratne SG, PifianoV G, Mansi JL, et al. Bisphosphonates induce ap- optosis in human breast cancer cell lines[J]. Br J Cancer,2000,82 (8) :1459.
  • 7Boissier S, Fen'eras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion:an early event in the for- mation of bone metastases[J]. Cancer Res,2000,60:2949.
  • 8Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid[J]. J Pharmacol Exp Thcr, 2002,302(3) :1055.
  • 9Rosen LS, David G, Simon T, et al. Long-term efiqeacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors:A randomized, phase Ⅲ double-blind,placebo-contmled trial[J]. Cancer,2004,100 (12) :2613.
  • 10吴瑾,周莉华,蒋晓东.唑来膦酸联合放疗治疗骨转移癌临床研究[J].实用癌症杂志,2007,22(4):404-406. 被引量:7

二级参考文献6

  • 1李增云,马庆彤,任晓,刘娜,陈树泉,王达,王健.唑来膦酸联合放疗治疗骨转移性疼痛的临床观察[J].四川肿瘤防治,2006,19(3):208-209. 被引量:11
  • 2赵洪瑜,仇晓军,王燕,季斌.放疗联合唑来膦酸治疗骨转移肿瘤疼痛34例临床分析[J].南通大学学报(医学版),2006,26(6):498-499. 被引量:6
  • 3Rosen LS,Gordon D,Tchekmedyian S,et al.Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors:a phase Ⅲ,double-blind,randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group[J].J Clin Oncol,2003,21(16):3150.
  • 4Coleman RE,Purohit OP.Osteoclast inhibition for the treatment of bone metastases[J].Cancer Treat Rev,1993,19(1):79.
  • 5Croucher P,Jagdev S,Coleman R.The anti-tumor potential of zoledronic acid[J].Breast Cancer,2003,12(Suppl 2):S30.
  • 6Wellington K,Goa KL.Zoledronic acid:a review of its use in the management of bone metastases and hypercalcaemia of malignancy[J].Drugs,2003,63(4):417.

共引文献84

同被引文献50

引证文献8

二级引证文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部